At acute and convalescent phases, COVID-19 positive subjects had significantly higher syndecan-1 [acute (p < 0.01); convalescent (p < 0.05)] and glypican-1 [acute and convalescent both p < 0.01)] breakdown compared with controls [both proteins below limit of detection]. The gene discussed is GPC1; the disease is COVID-19.